Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference

Bruno, Ricardo Vasconcellos; Ávila, Márcio Augusto Pinto de; Neves, Fernanda Baleeiro; Nardi, Antônio Egídio; Crespo, Clícia Márcia Santos; Sobrinho, Antonio Tavares Carneiro

doi:10.1016/j.fertnstert.2006.11.133

Cited by 38 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, metformin appears to accumulate in erythro 0 cytes and consequently may be a part of a deep compartment for the drug [26], which supposes to affect the pharmacokinetics of the drug; such finding could explain our results, which also in accordance with the results reported by Marchetti et al who demonstrated that metformin plasma level was not correlated with plasma glucose and HbA1c [27]. Bruno et al compared two doses of metformin (1500 mg and 2500 mg), with BMI and waist circumference as their primary end point [28]. A significant drop in BMI and waist circumference was seen in the group using the higher of the two doses.…”

Section: Discussionsupporting

confidence: 92%

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Kadhim¹,

Ismael²,

Khalaf³

et al. 2012

JDM

View full text Add to dashboard Cite

Despite the extensive clinical experience with the use of metformin worldwide, no formal doseranging study has been conducted because the current dosing strategy of metformin was determined empirically, rather than by an understanding of its dose-response relationship in patients with type 2 diabetes. The present study was designed to evaluate the correlation between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes. Sixty type 2 diabetic females were recruited for the study and were allocated into 3 groups; each receiving metformin 1000, 1500 and 2000 mg/day respectively for 3 months. Blood samples withdrawn from each patient at zero time and after 3 months is used to evaluate serum levels of HbA1c, glucose, leptin and insulin, in addition, the measurement of serum level of metformin in blood after 3 months by HPLC. The results demonstrated that all the treated groups with different doses of metformin showed significant improve in all parameters; the use of increased metformin doses was only correlated with plasma leptin levels in the highest dose. In conclusion, serum metformin levels are not good predictors for correlating improvement in clinical and biochemical parameters with increasing the dose in newly diagnosed non-insulin resistant females with type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 92%

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Kadhim¹,

Ismael²,

Khalaf³

et al. 2012

JDM

View full text Add to dashboard Cite

show abstract

“…In fact, as has already been suggested by other investigators (29,30), the dose of metformin may be essential for a good response and for the success of the treatment. In our study, women who did not respond to 1700 mg daily of metformin might have shown a clinical response if higher doses had been used.…”

Section: Discussionmentioning

confidence: 73%

Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome

Palomba

Falbo

Orio

et al. 2009

Fertility and Sterility

View full text Add to dashboard Cite

“…Man beginnt mit 500 mg täglich und erhöht alle 3-5 Tage um je 500 mg. Bei einer Dosierung von 1,5 g kann die Wirksamkeit der Therapie durch das Einsetzen von ovulatorischen Zyklen und die Besserung des Hyperandrogenismus nach 3 Monaten validiert werden. Sollte der Therapieerfolg ausbleiben, kann das Metformin bis zu 2-2,5 g pro Tag gesteigert werden [31].…”

Section: Metforminunclassified

Syndrom der polyzystischen Ovarien (PCOS)

Weiss

Hadziomerovic

2008

Gynäkologe

View full text Add to dashboard Cite

Die Pathophysiologie des Syndroms der polyzystischen Ovarien (PCOS) ist nach wie vor rätselhaft, obwohl die Erkrankung schon seit nahezu 100 Jahren bekannt ist. Im Jahr 1935 wurde das PCOS mit Amenorrhö, Hirsutismus und Adipositas mit vergrößerten Ovarien erstmals beschrieben [12]. Später kamen weitere Symptome wie Alopezie, Insulinresistenz, eine erhöhte Abortrate und sogar ein erhöhtes Risiko für ein Endometriumkarzinom dazu. Etwa 5-10% der Frauen im fertilen Alter leiden unter den Folgen des PCOS [13].

show abstract

Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference

Cited by 38 publications

References 20 publications

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome

Syndrom der polyzystischen Ovarien (PCOS)

Contact Info

Product

Resources

About